Zevra Therapeutics (NASDAQ:ZVRA) Price Target Cut to $23.00 by Analysts at Canaccord Genuity Group

Zevra Therapeutics (NASDAQ:ZVRA) had its target price cut by Canaccord Genuity Group from $25.00 to $23.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also commented on ZVRA. Guggenheim started coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target on the stock. Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Maxim Group boosted their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Trading Down 1.2 %

Shares of ZVRA stock traded down $0.11 during trading hours on Thursday, hitting $8.92. The company had a trading volume of 216,386 shares, compared to its average volume of 543,138. Zevra Therapeutics has a fifty-two week low of $4.18 and a fifty-two week high of $9.21. The company’s fifty day moving average is $7.97 and its 200 day moving average is $6.44. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market capitalization of $469.35 million, a PE ratio of -4.58 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The firm had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. During the same quarter last year, the firm earned ($0.15) earnings per share. Research analysts expect that Zevra Therapeutics will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in ZVRA. Vestal Point Capital LP acquired a new stake in shares of Zevra Therapeutics during the third quarter worth approximately $3,644,000. Stonepine Capital Management LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $4,858,000. MetLife Investment Management LLC increased its position in shares of Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after buying an additional 1,717 shares during the period. Rubric Capital Management LP bought a new position in shares of Zevra Therapeutics in the third quarter valued at $139,000. Finally, Propel Bio Management LLC purchased a new stake in Zevra Therapeutics during the third quarter worth about $1,248,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.